Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis

Bibliography

• KAHN J, MEHRABAN F, INGLE G et al.: Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. (2000) 156:1887-1900.
   PubMed Web of Science ®Google Scholar
• DAVIS GE, SENGER DR: Endothelial matrix, biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel formation. Circ. Res. (2005) 97:1093-1107.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, RISSANEN TT, VAJANTO I, HARTIKAINEN J: Vascular endothelial growth factors: biology, and current status of clinical amplications in cardiovascular medicine. J. Am. Coll. Cardiol. (2007) 49:1015-1026.
   PubMed Web of Science ®Google Scholar
• KISELYOV A, BALAKIN KV, TKACHENKO SE: VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs (2007) 16(1):83-107.
   PubMed Web of Science ®Google Scholar
• PANG RW, POON RT. Clinical implications of angiogenesis in cancers. Vasc. Health Risk Manag. (2006) 2:97-108.
   PubMedGoogle Scholar
• NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature (1998) 395:137-143.
   PubMed Web of Science ®Google Scholar
• DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. (1999) 20:649-688.
   PubMed Web of Science ®Google Scholar
• BRAISSANT O, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β- and -γ in the adult rat. Endocrinology (1996) 137:354-366.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, FORMAN BM, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA (1994) 91:7355-7359.
   PubMed Web of Science ®Google Scholar
• FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. (1997) 272:18779-18789.
   PubMed Web of Science ®Google Scholar
• FEIGE JN, GELMAN L, MICHALIK L, DESVERGNE B, WAHLI W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progr. Lipid Res. (2006) 45:120-159.
   PubMed Web of Science ®Google Scholar
• BERGER J, MOLLER DE: The mechanisms of action of PPARs. Ann. Rev. Med. (2002) 53:409-435.
   PubMed Web of Science ®Google Scholar
• GEARING KL, GOTTLICHER M, TEBOUL M, WIDMARK E, GUSTAFSSON JA: Interaction of the peroxisome proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA (1993) 90:1440-1444.
   PubMed Web of Science ®Google Scholar
• TOLON RM, CASTILLO AI, ARANDA A: Activation of the prolactin protein gene by peroxisome proliferator-activated receptor-α appears to be DNA binding-independent. J. Biol. Chem. (1998) 273:26652-26661.
   PubMed Web of Science ®Google Scholar
• RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79-82.
   PubMed Web of Science ®Google Scholar
• FEINSTEIN DL, SPANGOLO A, AKAR C et al.: Receptor-independent actions of PPAR thiazolidinedione agonists: is a mitochondrial function the key? Biochem. Pharm. (2005) 70:177-188.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, BROWN PJ, STRENBACH DD, HENKE BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43:527-550.
   PubMed Web of Science ®Google Scholar
• SCHOPFER GJ, LIN Y, BAKER PRS et al.: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc. Natl. Acad. Sci. USA (2005) 102:2340-2345.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferator-activated receptor γ (PPARγ). J. Biol. Chem. (1995) 270:12953-12956.
   PubMed Web of Science ®Google Scholar
• HENKE B, BLANCHARD SB, BRACKEEN MF et al.: N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. (1998) 41:5020-5036.
   PubMed Web of Science ®Google Scholar
• COLLINS JL, BLANCHARD SB, BOSWELL EG et al.: N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure–activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem. (1998) 41:5037-5054.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, LENHARD JM, OLIVER BB, RINGOLD GM, KLIEWER SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1997) 272:3406-3410.
   PubMed Web of Science ®Google Scholar
• WYSOWSKI DK, ARMSTRONG G, GOVERNALE L: Rapid increase in the use of oral antidiabetic drugs in the United States, 1990 – 2001. Diabetes Care (2003) 26:1852-1855.
   PubMed Web of Science ®Google Scholar
• THEOCHARIS S, MARGELI A, VIELH P, KOURAKLIS G: Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators. Cancer Treat. Rev. (2004) 30:545-554.
   PubMed Web of Science ®Google Scholar
• HAMERMAN D: Osteoporosis and atheroslerosis: biological linkages and the emergence of dual-purpose therapies. Q. J. Med. (2005) 98:467-484.
   Google Scholar
• PERSHADSINGH HA: Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Investig. Drugs (2004) 13(3):215-228.
   PubMed Web of Science ®Google Scholar
• GIAGINIS C, TSANTILI-KAKOULIDOU A, THEOCHARIS S: Peroxisome proliferator-activated receptor-γ ligands as bone turnover modulators. Expert Opin. Investig. Drugs (2007) 16(2):195-207.
   PubMed Web of Science ®Google Scholar
• GIAGINIS C, THEOCHARIS S, TSANTILI-KAKOULIDOU A: A consideration of PPAR-γ ligands with respect to lipophilicity: current trends and perspectives. Expert Opin. Investig. Drugs (2007) 16(4):413-417.
   PubMed Web of Science ®Google Scholar
• MARGELI A, KOURAKLIS G, THEOCHARIS S: Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands in angiogenesis. Angiogenesis (2003) 6:165-169.
   PubMedGoogle Scholar
• HAN S, ROMAN J: Peroxisome proliferator-activated receptor-γ: a novel target for cancer therapeutics? Anticancer Drugs (2007) 3:237-244.
   Web of Science ®Google Scholar
• THEOCHARIS S, MARGELI A, KOURAKLIS G: Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr. Med. Chem. Anticancer Agents (2003) 3:239-251.
   PubMedGoogle Scholar
• ASANO A, IRIE Y, SAITO M: Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes. Mol. Cell. Endocrinol. (2001) 174:71-76.
   PubMed Web of Science ®Google Scholar
• XIN X, YANG S, KOWALSKI J, GERRITSEN ME: Peroxisome proliferator-activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. (1999) 274:9116-9121.
   PubMed Web of Science ®Google Scholar
• MURATA T, HE S, HANGAI M et al.: Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2000) 41:2309-2317.
   PubMed Web of Science ®Google Scholar
• BISHOP-BALEY D, HLA T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-δ12,14-prostaglandin J2. J. Biol. Chem. (1999) 274:17042-17048.
   PubMed Web of Science ®Google Scholar
• FREED MI, ALLEN A, JORKASKY DK, DICICCO RA: Systematic exposure to rosiglitazone is unaltered by food. Eur. J. Clin. Pharmacol. (1999) 55:53-56.
   PubMed Web of Science ®Google Scholar
• SHEU WH, OU HC, CHOU FP, LIN TM, YANG CH: Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci. (2006) 78:1520-1528.
   PubMed Web of Science ®Google Scholar
• SARAYBA MA, LI L, TINGSIRIPAT T et al.: Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand. Exp. Eye Res. (2005) 80:435-442.
   PubMed Web of Science ®Google Scholar
• SASSA Y, HATA Y, AIELLO LP et al.: Bifunctional properties of peroxisome proliferator-activated receptor-γ1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes (2004) 53:1222-1229.
   PubMed Web of Science ®Google Scholar
• KIM KY, CHEON HG: Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor γ-activated Maxi-K channel opening in human umbilical vein endothelial cells. J. Biol. Chem. (2006) 281:13503-13512.
   PubMed Web of Science ®Google Scholar
• CHO DH, CHOI YJ, JO SA, JO I: Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone. Evidence for involvement of the peroxisome proliferator-activated receptor (PPAR)-γ dependent and PPAR-γ independent signaling pathways. J. Biol. Chem. (2004) 279:2499-2506.
   PubMed Web of Science ®Google Scholar
• BARAK Y, NELSON MC, ONG ES et al.: PPAR γ is required for placental, cardiac, and adipose tissue development. Mol. Cell. (1999) 4:585-595.
   PubMed Web of Science ®Google Scholar
• CRAWFORD SE, QI C, MISRA I et al.: Defects of the heart, eye, and megakaryocytes in peroxisome proliferator-activated receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. J. Biol. Chem. (2002) 277:3585-3592.
   PubMed Web of Science ®Google Scholar
• HUANG H, Campell SC, BEDFORD DF et al.: Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol. Cancer Res. (2004) 2:541-550.
   PubMed Web of Science ®Google Scholar
• RUIZ-VELASCO N, DOMINGUEZ A, VEGA MA: Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol. (2004) 67:303-313.
   PubMed Web of Science ®Google Scholar
• FEBBRAIO M, HAJJAR DP, SILVERSTEIN RL: CD36: a class B scavenger receptor involved in angiogenesis, inflammation, and lipid metabolism. J. Clin. Invest. (2001) 108:785-791.
   PubMed Web of Science ®Google Scholar
• FRUHBECK G: Intracellular signaling pathways activated by leptin. Biochem. J. (2006) 393:7-20.
   PubMed Web of Science ®Google Scholar
• SIERRA-HONIGMANN MR, NATH AK, MURAKAMI C et al.: Biological action of leptin as an angiogenic factor. Science (1998) 281:1683-1686.
   PubMed Web of Science ®Google Scholar
• QIAN H, HAUSMAN GJ, COMPTON et al.: Leptin regulation of peroxisome proliferator-activated receptor-γ, TNF, and uncoupling protein-2 expression in adipose tissues. Biochem. Biophys. Res. Commun. (1998) 246:660-667.
   PubMed Web of Science ®Google Scholar
• RIEUSSET J, AUWERX J, VIDAL H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor-γ with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. (1999) 265:265-271.
   PubMed Web of Science ®Google Scholar
• GOETZE S, BUNGENSTOCK A, CZUPALLA C et al.: Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands. Hypertension (2002) 40:748-754.
   PubMed Web of Science ®Google Scholar
• PANIGRAPHY D, SINGER S, SHEN LQ et al.: PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. (2002) 110:923-932.
   PubMed Web of Science ®Google Scholar
• YUAN J, TAKAHASHI T, MASUMORI N et al.: Ligands for peroxisome proliferator-activated receptor γ have potent antitumor effect against human renal cell carcinoma. Urology (2005) 65:594-599.
   PubMed Web of Science ®Google Scholar
• KESHAMOUNI VG, ARENBERG DA, REDDY RC et al.: PPAR-γ activation inhibits angiogenesis by blocking ELR-CXC chemokine production in non-small cell lung cancer. Neoplasia (2005) 7:294-301.
   PubMed Web of Science ®Google Scholar
• FU Y-G, SUNG JJY, WU K-C et al.: Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through downregulation of angiopoietin. Cancer Lett. (2006) 243:246-254.
   PubMed Web of Science ®Google Scholar
• COPLAND JA, MARLOW LA, KURAKATA K et al.: Novel high-affinity PPAR-γ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene (2006) 25:2304-2317.
   PubMed Web of Science ®Google Scholar
• VOGT T, HAFNER C, BROSS K et al.: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 98:2251-2256.
   PubMed Web of Science ®Google Scholar
• CORAS B, HAFNER C, REICHLE A et al.: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in a patient with endemic Kaposi sarcoma. Arch. Dermatol. (2004) 140:1504-1507.
   PubMed Web of Science ®Google Scholar
• NIJSTEN T, GELUYCKENS E, COLPAERT C et al.: Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J. Cutan. Pathol. (2005) 32:340-347.
   PubMed Web of Science ®Google Scholar
• ARTWOHL M, FURNSINN C, WALDHAUSL W et al.: Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARγ-independent mechanism. Diabetologia (2005) 48:586-594.
   PubMed Web of Science ®Google Scholar
• JOZKOWICZ A, DULAK J, PIATKOWSKA E et al.: Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim. Pol. (2000) 47:1147-1157.
   PubMed Web of Science ®Google Scholar
• YAMAKAWA K, HOSOI M, KOYAMA H et al.: Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (2000) 271:571-574.
   PubMed Web of Science ®Google Scholar
• PISTROSCH F, HERBRIG K, OELSCHLAEGEL U et al.: PPAR-γ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis (2005) 183:163-167.
   PubMed Web of Science ®Google Scholar
• WANG CH, TING MK, VERMA S et al.: Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. (2006) 152:1051E1-1051E8.
   Web of Science ®Google Scholar
• WANG CH, CILIBERTI N, LI SH et al.: Rosiglitazone facilitates angiogenic progenitor cell differentiation towards endothelial lineage. Circulation (2004) 109:1392-1400.
   PubMed Web of Science ®Google Scholar
• GENSCH C, CLEVER YP, WERNER C et al.: The PPAR-γ agonist rosiglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis (2007) 192:67-74.
   PubMed Web of Science ®Google Scholar
• CHINTALGATTU V, HARRIS GS, AKULA SM et al.: PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc. Res. (2007) 74:140-150.
   PubMed Web of Science ®Google Scholar
• CHU K, LEE S-T, KOO J-S et al.: Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after local cerebral ischemia. Brain Res. (2006) 1093:208-218.
   PubMed Web of Science ®Google Scholar
• EIBL G, TAKATA Y, BOROS LG et al.: Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. (2005) 65:982-990.
   PubMed Web of Science ®Google Scholar
• HASLMAYER P, THALHAMMER T, JAGER W et al.: The peroxisome proliferator-activated receptor γ ligand 15-deoxy-Δ 12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. (2002) 21:915-920.
   PubMed Web of Science ®Google Scholar
• KIM EH, NA HK, SURH YZ: Upregulation of VEGF expression by 15-deoxy-Δ 12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann. NY Acad. Sci. (2006) 1090:375-384.
   PubMed Web of Science ®Google Scholar
• FAUCONNET S, LASCOMBE I, CHABANNES E et al.: Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J. Biol. Chem. (2002) 277:23354-23343.
   Web of Science ®Google Scholar
• NESTO RW, BELL D, BONOW RO et al.: Thiazolidinedione use, fluid retention, and congestive heart disease. Diabetes Care (2004) 27:256-263.
   PubMed Web of Science ®Google Scholar
• CLAESSON-WELSH L: Signal transduction by vascular endothelial growth factor receptors. Biochem. Soc. Trans. (2003) 31:20-24.
   PubMed Web of Science ®Google Scholar
• BABA T, SHIMADA K, NEUGEBAUER S et al.: The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in Type 2 diabetic patients. Diabetes Care (2001) 24:953-954.
   PubMed Web of Science ®Google Scholar
• SOTIROPOULOS KB, CLERMONT A, YASUDA Y et al.: Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effectson edema and weight gain. FASEB J. (2006) 20:E367-E380.
   Google Scholar